Lilly to acquire sleep drug biotech firm Centessa in $6.3 billion deal
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The SCOUT-HCM trial hit its primary endpoint, showing a clinically meaningful and statistically significant reduction in Valsalva left ventricular outflow tract
Price of the starting dose of Ozempic and Wegovy reduced by 36% and 48% respectively
The partnership will focus on advancing fault-tolerant quantum algorithms and developing clinically relevant quantum applications
Hyderabad emerged as Lonza’s preferred destination after an extensive global evaluation process
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
The study showed a statistically significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 compared with placebo
Backed by two CAP - accredited genomics labs in Delhi NCR and Mumbai, supporting oncology, reproductive health, neurology, transplant immunology, and rare diseases
Subscribe To Our Newsletter & Stay Updated